Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Clinician Phone Checks After HF Discharge: No Doctors Needed?

Published: Thu, 20 Sep 2018 14:09:35 EDT
Nonphysicians phoned patients within a week in lieu of follow-up doctor appointments in the THRIVE trial; 30-day outcomes didn't change. A prominent observer says the strategy may be truly disruptive.
Medscape Medical News

Obesity Doubles Risk of Incontinence in Younger Women

Published: Thu, 20 Sep 2018 13:48:18 EDT
Clinicians should counsel women that maintaining a healthy weight may help prevent urinary incontinence now or later in life, the authors suggest.
Medscape Medical News

Can NPs and PAs Replace Hospitalists?

Published: Thu, 20 Sep 2018 12:18:45 EDT
Are physician-extenders just as capable of caring for patients as hospitalists are?
Medscape Hospital Medicine

Diagnosing Diabetes With a Single Blood Sample

Published: Thu, 20 Sep 2018 12:01:07 EDT
What is the clinical utility of a single-sample confirmatory definition of diabetes? Dr Elizabeth Selvin discusses the results of her study.
Medscape Diabetes & Endocrinology
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


Corbus nets over 600 endocannabinoid-related compounds, planning to develop 1-2 per year

Published: Thu, 20 Sep 2018 13:36:48 +0000
Corbus Pharmaceuticals Holdings has licensed worldwide rights to drug candidates from more than 600 compounds targeting the endocannabinoid system from Jenrin Discovery—which it says will fuel one to two new clinical programs in inflammatory and fibrotic diseases each year, starting in 2020.

Trial takes FibroGen’s renal anemia drug closer to EU filing

Published: Thu, 20 Sep 2018 12:51:58 +0000
FibroGen’s partner Astellas has reported phase 3 data that could support filings of their HIF inhibitor in Europe as an oral alternative to EPO drugs.

Exicure plans checkpoint combo after TLR9 drug clears early test

Published: Thu, 20 Sep 2018 12:00:07 +0000
Exicure is set to move toll-like receptor 9 (TLR9) agonist AST-008 into a phase 1b/2 trial after getting a look at data from healthy volunteers. The first-in-human clinical trial suggested that AST-008 is safe, tolerable and boosts cytokine levels.

Amicus joins gene therapy surge with $100M pipeline purchase

Published: Thu, 20 Sep 2018 11:22:27 +0000
Amicus Therapeutics has paid $100 million to buy Celenex. The takeover gives Amicus a ready-made pipeline of 10 gene therapies, including two that are in clinical trials.
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy